Can-Fite BioPharma Ltd. (CANF) Form 6-K — Nov 2, 2026
Can-Fite BioPharma announced that the Eurasian Patent Office has issued a notification of readiness to grant a patent covering Piclidenoson for diseases associated with OCRL deficiency, including Lowe syndrome and Dent disease 2. The patent application is owned by Fondazione Telethon, and under their collaboration agreement Can-Fite holds rights to develop, commercialize, and out-license Piclidenoson for Lowe syndrome. An open-label Phase 2 trial in 5 adult patients is underway with renal uptake of 99mTc-DMSA as the primary endpoint.
Key figures
- Phase2 patient count
- 5
- Trial duration months
- 6
- Canfite patients dosed to date
- over 1,600 patients in clinical studies
- Telethon research investment eur
- more than 660 million euros
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.